CNS specialist Neuraxpharm has snapped up the Lazap olanzapine brand in Greece from local firm Lyofin, helping to further expand its presence in the Greek market following a recent acquisition.
European central nervous system specialist Neuraxpharm has struck a deal to acquire the Lazap olanzapine brand in Greece from local player Lyofin, enabling Neuraxpharm to further expand in the Greek market.
In March last year, Neuraxpharm gained a significant foothold in Greece through the acquisition of Athens-based Brain Therapeutics (see sidebar).
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
